Your browser doesn't support javascript.
loading
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.
Redondo, Alba M; Valcárcel, David; González-Rodríguez, Ana P; Suárez-Lledó, María; Bello, José L; Canales, Miguel; Gayoso, Jorge; Colorado, Mercedes; Jarque, Isidro; Del Campo, Raquel; Arranz, Reyes; Terol, María J; Rifón, José J; Rodríguez, María J; Ramírez, María J; Castro, Nerea; Sánchez, Andrés; López-Jiménez, Javier; Montes-Moreno, Santiago; Briones, Javier; López, Aurelio; Palomera, Luis; López-Guillermo, Armando; Caballero, Dolores; Martín, Alejandro.
  • Redondo AM; Department of Haematology, Hospital Universitario de Salamanca - IBSAL, CIBERONC, Salamanca, Spain.
  • Valcárcel D; Department of Haematology, Hospital Vall d'Hebron, University Autònoma of Barcelona (UAB), Barcelona, Spain.
  • González-Rodríguez AP; Experimental Haematology Unit, Vall d' Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Suárez-Lledó M; Department of Haematology, Hospital Central de Asturias, Oviedo, Spain.
  • Bello JL; Department of Haematology, Hospital Clinic, Barcelona, Spain.
  • Canales M; Department of Haematology, Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain.
  • Gayoso J; Department of Haematology, Hospital La Paz, Madrid, Spain.
  • Colorado M; Department of Haematology, Hospital Gregorio Marañón, Madrid, Spain.
  • Jarque I; Department of Haematology, Hospital Marqués de Valdecilla, Santander, Spain.
  • Del Campo R; Department of Haematology, Hospital Universitario La Fe, CIBERONC, Valencia, Spain.
  • Arranz R; Department of Haematology, Hospital Son Llítzer, Palma de Mallorca, Spain.
  • Terol MJ; Department of Haematology, Hospital de La Princesa, Madrid, Spain.
  • Rifón JJ; Department of Haematology, Hospital Clínico de Valencia, Valencia, Spain.
  • Rodríguez MJ; Department of Haematology, Clínica Universitaria de Navarra, Pamplona, Spain.
  • Ramírez MJ; Department of Haematology, Hospital Universitario de Canarias, Las Palmas de Gran Canaria, Spain.
  • Castro N; Department of Haematology, Hospital de Jerez, Jerez de la Frontera, Spain.
  • Sánchez A; Department of Haematology, Hospital 12 de Octubre, Madrid, Spain.
  • López-Jiménez J; Department of Haematology, Hospital Virgen de la Arrixaca, Murcia, Spain.
  • Montes-Moreno S; Department of Haematology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Briones J; Department of Pathology, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain.
  • López A; Department of Haematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain.
  • Palomera L; Department of Haematology, Hospital Arnau de Villanova, Valencia, Spain.
  • López-Guillermo A; Department of Haematology, Hospital Clínico de Zaragoza, Zaragoza, Spain.
  • Caballero D; Department of Haematology, Hospital Clinic, Barcelona, Spain.
  • Martín A; Department of Haematology, Hospital Universitario de Salamanca - IBSAL, CIBERONC, Salamanca, Spain.
Br J Haematol ; 184(5): 797-807, 2019 03.
Article en En | MEDLINE | ID: mdl-30548583
ABSTRACT
We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen (BendaEAM) as conditioning for autologous stem-cell transplantation (ASCT) in patients with aggressive lymphomas. The primary endpoint was 3-year progression-free survival (PFS). Sixty patients (median age 55 [28-71] years) were included. All patients (except one who died early) engrafted after a median of 11 (9-72) and 14 (4-53) days to achieve neutrophil and platelet counts of >0.5 × 109 /l and >20 × 109 /l, respectively. Non-relapse mortality at 100 days and 1 year were 3.3% and 6.7%, respectively. With a median follow-up of 67 (40-77) months, the estimated 3-year PFS and overall survival (OS) were 58% and 75%, respectively. Patients in partial response at study entry had significantly worse PFS and OS than patients who underwent ASCT in complete metabolic remission, and this was the only prognostic factor associated with both PFS (Relative risk [RR], 0.27 [95% confidence interval {CI} [0.12-0.56]) and OS (RR, 0.40 [95% CI 0.17-0.97]) in the multivariate analysis. BendaEAM conditioning is therefore a feasible and effective regimen in patients with aggressive lymphomas. However, patients not in complete metabolic remission at the time of transplant had poorer survival and so should be considered for alternative treatment strategies.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Acondicionamiento Pretrasplante / Trasplante de Células Madre de Sangre Periférica / Clorhidrato de Bendamustina / Linfoma Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Acondicionamiento Pretrasplante / Trasplante de Células Madre de Sangre Periférica / Clorhidrato de Bendamustina / Linfoma Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2019 Tipo del documento: Article